Guardant Health announced the launch of its Shield™ multi‑cancer detection (MCD) laboratory‑developed test in Hong Kong, Singapore, and the Philippines, with availability beginning in April 2026. The rollout is made possible through a partnership with Manulife, a leading insurer with a presence in 10 Asian markets.
The Shield MCD test is a methylation‑based blood test that detects 10 common cancers—bladder, colorectal, breast, prostate, esophageal, gastric, liver, lung, ovarian, and pancreatic. In clinical studies it achieved a specificity of 98.5 % and an overall sensitivity of 60 %, rising to 74 % for six aggressive cancers. For colorectal cancer alone, the test showed 83 % sensitivity and 90 % specificity in the ECLIPSE study. The test builds on Guardant’s FDA‑approved colorectal screening test from July 2024 and carries a Breakthrough Device Designation for multi‑cancer detection.
Manulife will be the first insurer in Asia to offer the Shield MCD test, leveraging its trusted brand and extensive distribution network. Guardant already supplies its Guardant360 liquid‑biopsy test to Manulife customers in Singapore; this partnership adds a preventive screening product to the insurer’s portfolio and provides Guardant with immediate market access in the three launch countries.
The expansion extends Guardant’s Shield portfolio beyond the United States, strengthening its global footprint and diversifying revenue streams. Guardant’s Q4 2025 results showed total revenue of $281.3 million, up 39 % year‑over‑year, and full‑year 2025 revenue of $981 million, up 33 % year‑over‑year. Shield screening tests sold 38,000 in Q4 and 87,000 in the full year, underscoring growing demand for early detection.
Cancer remains a leading cause of death in Asia, creating a large unmet need for non‑invasive screening. Guardant’s entry into Hong Kong, Singapore, and the Philippines positions the company to capture a significant share of the early‑detection market, where demand for blood‑based tests is rising. The partnership signals Guardant’s strategy to accelerate global adoption of its precision oncology diagnostics.
Management comments: AmirAli Talasaz, co‑CEO, said the launch marks a critical milestone in expanding global access to early detection. Simranjit Singh, CEO of Guardant Health AMEA, highlighted the potential to lift screening rates across the region. Steve Finch, President and CEO of Manulife Asia, emphasized the insurer’s commitment to innovative health solutions.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.